Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir™, Seprehvec™) and a Tyrosine Kinase Inhibitor (Abivertinib). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™, COVI-DROPS™, SALICYN – 30 and MESENCHYMAL STEM CELL; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to developing and commercializing medicines for Saving-Life™ and Improving-Life™ is also demonstrated by our efforts to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and by ZTlido® (lidocaine topical system) 1.8%, for post-herpetic neuralgia (PHN). Resiniferatoxin is completing (i) a phase IB trial for intractable pain associated with cancer; and (ii) a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
Data Provided by Refinitiv. Minimum 15 minutes delayed.